2022
Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma
Luo W, Nagaria T, Sun H, Ma J, Lombardo J, Bassett R, Cao A, Tan D. Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. Pathology & Oncology Research 2022, 28: 1610293. PMID: 35221802, PMCID: PMC8863590, DOI: 10.3389/pore.2022.1610293.Peer-Reviewed Original ResearchConceptsGastric cancerPrognostic valueGastric adenocarcinomaMcl-1Pathologic TNM stageDifferent treatment modalitiesCancer-related deathPotential prognostic valueFurther subgroup analysisNegative prognostic markerTumor heterogeneityDifferent molecular alterationsSOX9 expressionSPOCK1 expressionPrognostic roleCommon malignancyPoor prognosisTNM stageTreatment modalitiesSubgroup analysisPrognostic markerUnivariate analysisDisease prognosisDivergent differentiationMolecular alterations
2021
NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
Luo W, Stevens T, Stafford P, Miettinen M, Gatalica Z, Vranic S. NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review. Current Oncology 2021, 28: 4485-4503. PMID: 34898574, PMCID: PMC8628659, DOI: 10.3390/curroncol28060381.Peer-Reviewed Original ResearchConceptsGenome-wide histone modificationsPost-meiotic spermatidsExpression of oncogenesTumor suppressor geneTranscription regulationHistone modificationsBromodomain proteinsNuclear proteinsRNA sequencingFusion proteinProtein productsSuppressor geneFusion partnerGenesSitu hybridizationDifferent clinical coursesProteinSkin adnexal tumorsPrimitive morphologyOncogenic driversInhibitor therapyClinical courseMolecular alterationsPrimitive tumorHematologic malignancies
2015
Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)
Luo W, Yu Z. Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investigation 2015, 2: 16. PMID: 27358884, PMCID: PMC4923638, DOI: 10.3978/j.issn.2306-9759.2015.08.01.Peer-Reviewed Original ResearchMyeloproliferative neoplasmsClinical presentationCALR mutationsClinical-molecular correlationsGene mutationsOptimal treatment strategyProtean clinical presentationsRisk of thrombosisHigher platelet countsCalreticulin mutationsCases of MPNCertain hematological parametersBetter prognosisPlatelet countTreatment strategiesHematological parametersMolecular alterationsMPL mutationsConventional morphological classificationHeterogeneous groupChromosomal alterationsPrognosisNeoplasmsCALRMolecular mechanisms